Sweden: Andersson replaces Jungnelius as CEO at Isofol Medical

By
Nick Herbert
-
Doctor hands holding blue ribbon, diabetes and Colorectal Cancer Awareness

Isofol Medical, a clinical-stage biotechnology company focused on developing and improving cancer treatment by increasing treatment efficacy through the use of cytostatics, has appointed Thomas Andersson as CEO of the company. He replaces Ulf Jungnelius who has resigned. Jungnelius, had been CEO of the company since 2019. Andersson brings experience from his roles in leading…

You must be a HMI Subscriber to view this content.

Subscribe Now »

RELATED ARTICLESMORE FROM AUTHOR